Overview

The Use of Midazolam and Remifentanil During Dialysis Access Procedures

Status:
Completed
Trial end date:
2016-04-30
Target enrollment:
Participant gender:
Summary
BACKGROUND: Sedation and analgesia are related to unexpected adverse events in chronic renal failure patients undergoing arteriovenous fistula placement procedures under monitored anesthesia care (MAC). OBJECTIVE: Our goal was to investigate and compare the sedation and analgesia related effects and adverse effects of continuous intravenous use of midazolam and intermittent bolus doses of midazolam while intravenous remifentanil is used as a rescue medication in patients with chronic renal failure.
Phase:
N/A
Details
Lead Sponsor:
Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital
Collaborator:
Trakya University
Treatments:
Midazolam
Remifentanil